Celastrol and Resveratrol Modulate SIRT Genes Expression and Exert Anticancer Activity in Colon Cancer Cells and Cancer Stem-like Cells.
Helena MoreiraAnna SzyjkaJustyna GrzesikKatarzyna PelcMagdalena ZukAnna KulmaFathi EmhemmedChristian D MullerKazimierz GąsiorowskiEwa BargPublished in: Cancers (2022)
Metastatic colorectal cancer (CRC) remains a hard-to-cure neoplasm worldwide. Its curability declines with successive lines of treatment due to the development of various cancer resistance mechanisms and the presence of colorectal cancer stem cells (CSCs). Celastrol and resveratrol are very promising phytochemicals for colon cancer therapy, owing to their pleiotropic activity that enables them to interact with various biological targets. In the present study, the anticancer activities of both compounds were investigated in metastatic colon cancer cells (LoVo cells) and cancer stem-like cells (LoVo/DX). We showed that celastrol is a very potent anti-tumor compound against metastatic colon cancer, capable of attenuating CSC-like cells at the molecular and cellular levels. In contrast, resveratrol has a much greater effect on colon cancer cells that are expressing standard sensitivity to anticancer drugs, than on CSC-like cells. In addition, both polyphenols have different influences on the expression of SIRT genes, which seems to be at least partly related to their anti-tumor activity.
Keyphrases
- papillary thyroid
- cancer stem cells
- squamous cell
- poor prognosis
- squamous cell carcinoma
- small cell lung cancer
- cancer therapy
- metastatic colorectal cancer
- oxidative stress
- genome wide
- lymph node metastasis
- induced apoptosis
- magnetic resonance
- drug delivery
- gene expression
- binding protein
- childhood cancer
- signaling pathway
- young adults
- dna methylation
- ischemia reperfusion injury
- long non coding rna
- high resolution
- low grade
- combination therapy